Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05722925
PHASE4

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Sponsor: OHSU Knight Cancer Institute

View on ClinicalTrials.gov

Summary

The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.

Official title: Prospective Study Evaluating the Role of Axumin® (Fluciclovine or 18F-FACBC) PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2023-10-04

Completion Date

2026-12-01

Last Updated

2025-11-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

Fluciclovine PET/CT

8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection

Locations (1)

Oregon Health & Science University

Portland, Oregon, United States